Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03097341
Recruitment Status : Completed
First Posted : March 31, 2017
Results First Posted : May 20, 2019
Last Update Posted : June 5, 2019
Sponsor:
Information provided by (Responsible Party):
Aronora, Inc.

Tracking Information
First Submitted Date  ICMJE March 21, 2017
First Posted Date  ICMJE March 31, 2017
Results First Submitted Date  ICMJE February 15, 2019
Results First Posted Date  ICMJE May 20, 2019
Last Update Posted Date June 5, 2019
Actual Study Start Date  ICMJE June 5, 2017
Actual Primary Completion Date January 16, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 23, 2019)
  • The Number of Subjects With Treatment-related Adverse Events (TEAEs) Will be Summarized Using Frequency Counts. [ Time Frame: From Subject Check-In through Follow up. Follow up was performed 7 days after Day 29. If the aPTT was not +/- 10% baseline or within normal range, subject was monitored weekly until baseline reached and follow up then occured 7 days after. ]
    TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.
  • The Number of Subjects With Abnormal Vital Signs That Are Related to Treatment Will be Summarized Using Frequency Counts.. [ Time Frame: From subject Check-In through Follow up. Follow up was performed 7 days after Day 29. If the aPTT was not +/- 10% baseline or within normal range, subject was monitored weekly until baseline reached and follow up then occured 7 days after. ]
    Vital sign measurements (body temperature, respiratory rate, blood pressure, and heart rate)
  • The Number of Subjects With Abnormal Electrocardiogram That is Related to Treatment Will be Summarized Using Frequency Counts.. [ Time Frame: From subject Check-In through Follow up. Follow up was performed 7 days after Day 29. If the aPTT was not +/- 10% baseline or within normal range, subject was monitored weekly until baseline reached and follow up then occured 7 days after. ]
    12-lead electrocardiogram measurement
  • The Number of Subjects With Abnormal Injection Site Reaction That Are Related to Treatment Will be Summarized Using Frequency Counts.. [ Time Frame: From Study Day 1 through Follow up. Follow up was performed 7 days after Day 29. If the aPTT was not +/- 10% baseline or within normal range, subject was monitored weekly until baseline reached and follow up then occured 7 days after. ]
    Injection site reaction (pain, tenderness, erythema/ redness, and induration/ swelling)
  • The Number of Subjects With Abnormal Laboratory Values and/ or Adverse Events That Are Related to Treatment Will be Summarized Using Frequency Counts.. [ Time Frame: From subject Check-In through Follow up. Follow up was performed 7 days after Day 29. If the aPTT was not +/- 10% baseline or within normal range, subject was monitored weekly until baseline reached and follow up then occured 7 days after. ]
    Clinical laboratory tests include serum chemistry, hematology, coagulation parameters (aPTT, PT, and bleeding time), and urinalysis
  • The Number of Subjects That Develop Treatment-related Immunogenicity Will be Summarized Using Frequency Counts. [ Time Frame: From Study Day 1 through Follow up. Follow up was performed 7 days after Day 29. If the aPTT was not +/- 10% baseline or within normal range, subject was monitored weekly until baseline reached and follow up then occured 7 days after. ]
    Immunogenicity measured by the presence of plasma anti-drug antibodies
Original Primary Outcome Measures  ICMJE
 (submitted: March 30, 2017)
The safety and tolerability of xisomab 3G3 will be measured by the number of subjects with treatment-related adverse events (TEAEs) and the number of TEAEs will be summarized using frequency counts. [ Time Frame: Between two and eight weeks ]
TEAEs will be assessed by physical examination, vital signs (body temperature, respiratory rate, blood pressure, and heart rate), electrocardiogram monitoring (12-lead), clinical laboratory tests (serum chemistry, hematology, coagulation parameters, and urinalysis), injection site reaction (pain, tenderness, erythema/ redness, and induration/ swelling), immunogenicity (plasma anti-drug antibodies) and AEs.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 15, 2019)
  • The Maximum Plasma Concentration (Cmax) of Xisomab 3G3 After a Single Injection Will be Measured in Each Subject. [ Time Frame: Pre-dose (0.5h prior to dose), 0.083, 0.25, 0.5, 1,3,8,24,72,120, 168, 216, 336, 504, 672h after dosing as well as follow up (7 days after aPTT returned back to baseline). ]
    Maximum plasma concentration of xisomab 3G3 was estimated based on plasma xisomab 3G3 concentrations. Non-compartmental PK data analysis was performed to estimate the plasma PK parameters of xisomab 3G3.
  • The Time to Reach Maximum Plasma Concentrations of Xisomab 3G3 (Tmax) After a Single Injection Will be Measured in Each Subject. [ Time Frame: Pre-dose (0.5h prior to dose), 0.083, 0.25, 0.5, 1,3,8,24,72,120, 168, 216, 336, 504, 672h after dosing as well as follow up (7 days after aPTT returned back to baseline). ]
    The time to reach maximum plasma concentrations of xisomab 3G3 after a single injection was estimated based on plasma xisomab 3G3 concentrations. Non-compartmental PK data analysis was performed to estimate the plasma PK parameters of xisomab 3G3.
  • The Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Non-zero Concentration (AUC0-t), as Calculated by the Linear Trapezoidal Method, After a Single Injection of Xisomab 3G3 Will be Calculated for Each Subject. [ Time Frame: Pre-dose (0.5h prior to dose), 0.083, 0.25, 0.5, 1,3,8,24,72,120, 168, 216, 336, 504, 672h after dosing as well as follow up (7 days after aPTT returned back to baseline). ]
    The area under the plasma concentration-time curve from time 0 to the last measurable non-zero concentration was estimated based on plasma xisomab 3G3 concentrations. Non-compartmental PK data analysis was performed to estimate the plasma PK parameters of xisomab 3G3.
  • The Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Subject. [ Time Frame: Pre-dose (0.5h prior to dose), 0.083, 0.25, 0.5, 1,3,8,24,72,120, 168, 216, 336, 504, 672h after dosing as well as follow up (7 days after aPTT returned back to baseline). ]
    The area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf) is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant. Non-compartmental PK data analysis was performed to estimate the plasma PK parameters of xisomab 3G3.
  • The Percent of AUC0-inf Extrapolated (AUC%Extrap) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Subject. [ Time Frame: Pre-dose (0.5h prior to dose), 0.083, 0.25, 0.5, 1,3,8,24,72,120, 168, 216, 336, 504, 672h after dosing as well as follow up (7 days after aPTT returned back to baseline). ]
    The percent of AUC0-inf extrapolated (AUC%extrap) is calculated by (1-AUC0-t/AUC0-inf)*100. Non-compartmental PK data analysis was performed to estimate the plasma PK parameters of xisomab 3G3.
  • The Apparent First Order Terminal Elimination Rate Constant (Kel) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject. [ Time Frame: Pre-dose (0.5h prior to dose), 0.083, 0.25, 0.5, 1,3,8,24,72,120, 168, 216, 336, 504, 672h after dosing as well as follow up (7 days after aPTT returned back to baseline). ]
    The apparent first order terminal elimination rate constant will be calculated from a semi-log plot of the plasma concentration versus time curve. The parameter will be calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations). Non-compartmental PK data analysis was performed to estimate the plasma PK parameters of xisomab 3G3.
  • The Apparent First Order Terminal Elimination Half-life (T1/2) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject. [ Time Frame: Pre-dose (0.5h prior to dose), 0.083, 0.25, 0.5, 1,3,8,24,72,120, 168, 216, 336, 504, 672h after dosing as well as follow up (7 days after aPTT returned back to baseline). ]
    The apparent first order terminal elimination half-life will be calculated as 0.693/Kel. Non-compartmental PK data analysis was performed to estimate the plasma PK parameters of xisomab 3G3.
  • The Apparent Total Plasma Clearance (CL) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject. [ Time Frame: Pre-dose (0.5h prior to dose), 0.083, 0.25, 0.5, 1,3,8,24,72,120, 168, 216, 336, 504, 672h after dosing as well as follow up (7 days after aPTT returned back to baseline). ]
    The apparent total plasma clearance will be calculated as [Dose/AUC0-inf]. Non-compartmental PK data analysis was performed to estimate the plasma PK parameters of xisomab 3G3.
  • The Total Apparent Volume of Distribution (Vss) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject. [ Time Frame: Pre-dose (0.5h prior to dose), 0.083, 0.25, 0.5, 1,3,8,24,72,120, 168, 216, 336, 504, 672h after dosing as well as follow up (7 days after aPTT returned back to baseline). ]
    The total apparent volume of distribution (Vss) will be calculated as the mean residence time x clearance. Non-compartmental PK data analysis was performed to estimate the plasma PK parameters of xisomab 3G3.
  • The Effect of a Single Intravenous Dose of Xisomab 3G3 on the Activated Partial Thromboplastin Time (aPTT) in Healthy Adult Subjects Will be Measured. [ Time Frame: Pre-dose (0.5h prior to dose), 1, 24,72, 168, 336, 504, 672h after dosing as well as follow up (7 days after day 29 or after aPTT returned back to baseline).. ]
    Activated partial thromboplastin time (aPTT) will be used as a surrogate pharmacodynamic marker.
Original Secondary Outcome Measures  ICMJE
 (submitted: March 30, 2017)
  • The Maximum Plasma Concentration (Cmax) of Xisomab 3G3 After a Single Injection Will be Measured in Each Subject. [ Time Frame: Between two and eight weeks ]
    Maximum plasma concentration of xisomab 3G3
  • The Time to Reach Maximum Plasma Concentrations of Xisomab 3G3 (Tmax) After a Single Injection Will be Measured in Each Subject. [ Time Frame: Between two and eight weeks ]
    The time to reach maximum plasma concentrations of xisomab 3G3 after a single injection
  • The Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Non-zero Concentration (AUC0-t), as Calculated by the Linear Trapezoidal Method, After a Single Injection of Xisomab 3G3 Will be Calculated for Each Subject. [ Time Frame: Between two and eight weeks ]
    The area under the plasma concentration-time curve from time 0 to the last measurable non-zero concentration
  • The Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Subject. [ Time Frame: Between two and eight weeks ]
    The area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf) is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.
  • The Percent of AUC0-inf Extrapolated (AUC%Extrap) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Subject. [ Time Frame: Between two and eight weeks ]
    The percent of AUC0-inf extrapolated (AUC%extrap) is calculated by (1-AUC0-t/AUC0-inf)*100.
  • The Apparent First Order Terminal Elimination Rate Constant (Kel) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject. [ Time Frame: Between two and eight weeks ]
    The apparent first order terminal elimination rate constant will be calculated from a semi-log plot of the plasma concentration versus time curve. The parameter will be calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).
  • The Apparent First Order Terminal Elimination Half-life (T1/2) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject. [ Time Frame: Between two and eight weeks ]
    The apparent first order terminal elimination half-life will be calculated as 0.693/Kel.
  • The Apparent Total Plasma Clearance (CL) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject. [ Time Frame: Between two and eight weeks ]
    The apparent total plasma clearance will be calculated as [Dose/AUC0-inf].
  • The Total Apparent Volume of Distribution (Vss) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject. [ Time Frame: Between two and eight weeks ]
    The total apparent volume of distribution (Vss) will be calculated as the mean residence time x clearance.
  • The Effect of a Single Intravenous Dose of Xisomab 3G3 on the Activated Partial Thromboplastin Time (aPTT) in Healthy Adult Subjects Will be Measured. [ Time Frame: Between two and eight weeks ]
    Activated partial thromboplastin time (aPTT) will be used as a surrogate pharmacodynamic marker.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects
Official Title  ICMJE A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Xisomab 3G3 in Healthy Adult Subjects
Brief Summary The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of xisomab 3G3 in healthy adult subjects.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Thrombosis
Intervention  ICMJE
  • Drug: xisomab 3G3- Dose 1
    Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
    Other Name: AB023- Dose 1
  • Drug: xisomab 3G3-Dose 2
    Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
    Other Name: AB023- Dose 2
  • Drug: xisomab 3G3-Dose 3
    Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
    Other Name: AB023- Dose 3
  • Drug: xisomab 3G3- Dose 4
    Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
    Other Name: AB023- Dose 4
  • Other: Placebo
    Participants will receive a single intravenous dose of placebo.
Study Arms  ICMJE
  • Experimental: xisomab 3G3- Dose 1
    Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
    Intervention: Drug: xisomab 3G3- Dose 1
  • Experimental: xisomab 3G3- Dose 2
    Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
    Intervention: Drug: xisomab 3G3-Dose 2
  • Experimental: xisomab 3G3- Dose 3
    Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
    Intervention: Drug: xisomab 3G3-Dose 3
  • Experimental: xisomab 3G3- Dose 4
    Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
    Intervention: Drug: xisomab 3G3- Dose 4
  • Placebo Comparator: Placebo
    Participants will receive a single intravenous dose of placebo.
    Intervention: Other: Placebo
Publications * Lorentz CU, Verbout NG, Wallisch M, Hagen MW, Shatzel JJ, Olson SR, Puy C, Hinds MT, McCarty OJT, Gailani D, Gruber A, Tucker EI. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809. doi: 10.1161/ATVBAHA.118.312328.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 30, 2017)
21
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE January 16, 2018
Actual Primary Completion Date January 16, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Healthy adult male and/or female (non-childbearing potential only), 18 to 48 years of age, inclusive, at screening.
  2. Continuous non-smoker who has not used nicotine containing products for at least 3 months prior to dosing and throughout the study.
  3. Body mass index (BMI) ≥ 19 and ≤ 29.0 (kg/m2) and weight between 50 and 125 kg (inclusive) at screening.
  4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.
  5. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), creatinine must be between the lower limit of normal (LLN; or up to 15% below LLN as not indicative of hepatic or renal disease in healthy subjects) and the upper limit of normal, inclusive, at screening and check-in.
  6. aPTT, PT/INR, and platelets, must be within the limits of normal, inclusive, at screening and check-in.
  7. Bleeding time must be between 2 to 8 minutes, inclusive, at check-in.
  8. For a female of non childbearing potential: must have undergone one of the following sterilization procedures at least 6 months prior to dosing:

    • hysteroscopic sterilization;
    • bilateral tubal ligation or bilateral salpingectomy;
    • hysterectomy;
    • bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to dosing and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status as per PI or designee judgment.
  9. A non vasectomized male subject whose sexual partner is sterile or was advised to use one of the following during the course of the study (or prior to study as specified) and for 90 days following dosing:

    • Abstain from sexual intercourse;
    • An intrauterine device with spermicide;
    • A physical barrier method (e.g., male or female condom, contraceptive sponge, diaphragm, cervical cap) with spermicide;
    • An intravaginal system (e.g., NuvaRing®) for at least 3 months prior to dosing;
    • An oral, implantable, transdermal, or injectable hormonal contraceptive for at least 3 months prior to dosing.

    No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to dosing. A male who has been vasectomized less than 4 months prior to dosing must follow the same restrictions as a non vasectomized male.

  10. If male, must agree to not donate sperm from dosing until 90 days after dosing.
  11. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria:

  1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  4. History or presence of drug abuse within the last 2 years prior to dosing.
  5. History of alcoholism within the last 2 years prior to dosing or a current history of imbibing 3 or more units of alcohol per day (1 unit is equivalent to 150 mL of wine or 360 mL of beer or 45 mL of 45% alcohol).
  6. History or presence of hypersensitivity or idiosyncratic reaction to the study drug, any ingredients of the study drug, or related compounds.
  7. History of a clinically significant allergy of any kind including a history of allergic or hypersensitivity reactions to any drugs.
  8. History or presence of:

    • Bleeding disorder(s) and/or at risk of bleeding, including relevant familial history;
    • Clinically significant anemia, in the opinion of the PI or designee;
    • Thromboembolic disease;
    • Bleeding in the gastrointestinal tract or central nervous system.
  9. Allergy to rodents.
  10. Had a minor surgery or major physical injury less than 4 weeks or major surgery less than 12 weeks prior to screening.
  11. Was hospitalized within 2 months of dosing, unless deemed acceptable by the PI or designee.
  12. Female subjects of childbearing potential.
  13. Female subjects who are pregnant or lactating.
  14. Positive urine drug or alcohol results at screening or check in.
  15. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).
  16. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
  17. Seated heart rate is lower than 40 bpm or higher than 100 bpm at screening.
  18. QTcF interval is >450 msec (males) or >460 msec (females) or has ECG findings deemed abnormal with clinical significance by the PI or designee at screening.
  19. Hemoglobin value of less than 11.5 g/dL for females and 13.0 g/dL for males, at screening or check-in.
  20. Unable to refrain from or anticipates the use of:

    • Any prescription medications, non-prescription medications, herbal remedies, or vitamin supplements beginning approximately 14 days prior to dosing and throughout the study. Acetaminophen (up to 2 g per 24 hour period) may be permitted during the study and will be documented.
    • Any anticoagulants (i.e., warfarin, Low Molecular Weight Heparin), coagulants, anti-platelet (e.g., clopidogrel), nonsteroidal anti-inflammatory drugs and/or acetylsalicylic acid beginning approximately 28 days prior to dosing and throughout the study. Appropriate sources will be consulted by the PI or designee to confirm lack of pharmacokinetic/pharmacodynamic interaction with study drug.
    • Any investigational drugs or biologics beginning approximately 30 days prior to dosing and throughout the study.
    • Any biologics developed from chinese hamster ovary cell cultures in their life time.
  21. Has been on a diet incompatible with the on study diet, in the opinion of the PI or designee, within the 28 days prior to dosing and throughout the study.
  22. Donation of blood or significant blood loss within 56 days prior to dosing.
  23. Plasma donation within 7 days prior to dosing.
  24. Strenuous exercise/physical activity which could cause muscle aches or injury, including contact sports at any time from 72 hours before dosing until completion of the study.
  25. Participation in another clinical study within 30 days prior to dosing. The 30 day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of the current study.
  26. Presence of any scars, or tattoos which may obscure the injection site, as deemed by PI or designee.
  27. Any condition or circumstance, in the opinion of the PI or designee, which may make the subject unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the subject's safety.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 48 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03097341
Other Study ID Numbers  ICMJE 3G3-15-01
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Plan Description: undecided
Responsible Party Aronora, Inc.
Study Sponsor  ICMJE Aronora, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Aronora, Inc.
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP